RayKnowChina Research Map
Shortlist0

Beijing

Beijing Hospital

北京医院

Listed for 17 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Beijing Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Hepatocellular carcinoma肝细胞癌15 papers led1 open trial led
  2. Stomach cancer胃癌4 papers led
  3. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  4. Neuroblastoma神经母细胞瘤1 paper led
  5. Multiple myeloma多发性骨髓瘤2 papers led
  6. Haemophilia A血友病 A2 papers led
  7. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜0 papers led
  8. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病0 papers led
  9. Myasthenia gravis重症肌无力11 papers led
  10. Moyamoya disease烟雾病4 papers led1 open trial led
  11. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led
  12. Takayasu arteritis大动脉炎1 paper led
  13. Idiopathic pulmonary fibrosis特发性肺纤维化8 papers led
  14. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  15. Behçet disease白塞病2 papers led
  16. IgA nephropathyIgA 肾病1 paper led
  17. Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
15
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 4420232024: 2220242025: 222025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
    Phase
    N/A
    Started
    2023-02
    Registry
    NCT05738980

    Age 18 years to 75 years (registered criteria)

    Led by Beijing HospitalBeijing

  2. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging, AI & early detectionHepatitis B & cirrhosisRecurrence & prognosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiology / nuclear medicine
Papers it led15
  1. Loss of mucosal tolerance to glycoprotein 2 isoform 1 is a potential novel diagnostic biomarker for cholangiocarcinoma.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  2. Prolonged recurrence-free survival by autologous rectronectin-activated killer (RAK) cells in resected high-risk hepatocellular carcinoma: an experimental single-arm phase II trial (pilot study).2025International journal of surgery (London, England)
  3. KLF15-activated MARCH2 boosts cell proliferation and epithelial-mesenchymal transition and presents diagnostic significance for hepatocellular carcinoma.2024Experimental cell research
  4. mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma.2024International journal of biological sciencesFree full text
  5. Role of Sonazoid enhanced ultrasound assistant laparoscopic radiofrequency ablation in treating liver malignancy-A single-center retrospective cohort study.2023Cancer medicineFree full text
  6. Small extrachromosomal circular DNAs as biomarkers for multi-cancer diagnosis and monitoring.2023Clinical and translational medicineFree full text
  7. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.2023Journal of cancer research and clinical oncologyFree full text
  8. The role of sex hormones and receptors in HBV infection and development of HBV-related HCC.2023Journal of medical virology
  9. DDX17 protects hepatocytes against oleic acid/palmitic acid-induced lipid accumulation.2022Biochemical and biophysical research communications
  10. DNA N6-Adenine methylation in HBV-related hepatocellular carcinoma.2022Gene
  11. [Structural Analysis of the 5'-Flanking Region of Human Alpha-Fetoprotein Encoding Gene].2022Molekuliarnaia biologiia
  12. Anatomic versus non-anatomic resection of hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.2021Asian journal of surgery
  13. Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study.2021BMC cancerFree full text
  14. CircMTO1 suppresses hepatocellular carcinoma progression via the miR-541-5p/ZIC1 axis by regulating Wnt/β-catenin signaling pathway and epithelial-to-mesenchymal transition.2021Cell death & diseaseFree full text
  15. Delivery of microRNA-21-sponge and pre-microRNA-122 by MS2 virus-like particles to therapeutically target hepatocellular carcinoma cells.2021Experimental biology and medicine (Maywood, N.J.)Free full text
All its trials on ClinicalTrials.gov, any status7
  1. Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3RecruitingNCT05738980Lead sponsorN/AStart 2023-02
  2. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  3. Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver CancerWithdrawnNCT05292443Study siteStart 2021-12
  4. Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCCStatus unknownNCT04920214Study siteStart 2021-01
  5. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  6. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  7. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 4 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.04%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChemotherapy & combined treatmentEarly detection & endoscopySurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led4
  1. Exploring the correlation and mechanism of natural killer cell cytotoxic sensitivity against gastric cancer.2025Oncology researchFree full text
  2. Impact of CYP2A6 Gene Polymorphism on the Efficacy and Safety of S-1 Therapy in Patients with Gastric Cancer: A Systematic Review and Meta-Analysis.2024Chemotherapy
  3. Gastroblastoma - a case report and literature review.2024World journal of surgical oncologyFree full text
  4. Modified Chaishao Liujunzi Decoction inhibits bile acid-induced gastric intestinal metaplasia: from network prediction to experimental verification.2023AgingFree full text
Chinese-language papers (not in the count)2
  1. [Comparison of prognosis of elderly patients with gastric and colorectal tumors receiving different nutritional support treatments].2024Zhonghua yi xue za zhi
  2. [The safety and efficacy of prophylactic hyperthermic intraperitoneal chemotherapy for elderly patients with locally advanced gastric cancer: a propensity score matching analysis].2023Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status5
  1. Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric CancerStatus unknownNCT03950141Lead sponsorPhase 2Start 2017-07
  2. Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity PatientsCompletedNCT05518929Study sitePhase 4Start 2022-09
  3. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  4. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  5. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesCAR-T & cell therapy

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 112025

15 hospitals in Beijing for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led no English-language PubMed papers on thrombotic thrombocytopenic purpura in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

8 hospitals in Beijing for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT06727669

    Age not stated (registered criteria)

    Led by Peking University People's Hospital; 4 listed hospitals as study sitesBeijing, Chongqing, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Longitudinal Cohort of Thrombosis and Hemostasis DiseasesRecruitingNCT06727669Study siteStart 2024-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led no English-language PubMed papers on neuromyelitis optica spectrum disorder in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

12 hospitals in Beijing for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08
  2. A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum DisordersTerminatedNCT03330418Study sitePhase 3Start 2018-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 11 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 2.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 7720232024: 2220242025: 112025

11 hospitals in Beijing for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07249632

    Age 12 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  3. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

  4. Not yet recruiting
    An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07818291

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesThymus & thymectomyBiologic & complement drugsCrisis & intensive care
Departments in papersNeurology
Papers it led11
  1. Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis.2025Daru : journal of Faculty of Pharmacy, Tehran University of Medical SciencesFree full text
  2. A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravis.2024European journal of neurologyRCTFree full text
  3. Thymoma negatively affects the neurological outcome of myasthenia gravis after thymectomy: a propensity score matching study.2024Journal of cardiothoracic surgeryFree full text
  4. Population PK/PD model of tacrolimus for exploring the relationship between accumulated exposure and quantitative scores in myasthenia gravis patients.2023CPT: pharmacometrics & systems pharmacologyFree full text
  5. Postoperative clinical outcomes of patients with thymic epithelial tumors after over-3-year follow-up at a single-center.2023Journal of cardiothoracic surgeryFree full text
  6. Analysis of influencing factors of perioperative myasthenic crisis in 387 myasthenia gravis patients without thymoma in a single center.2023Journal of cardiothoracic surgeryFree full text
  7. Coexisting Stiff Limb Syndrome, Myositis, and Myasthenia Gravis in a Patient with Thymoma.2023The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  8. Surgical safety analysis and clinical experience sharing of myasthenia gravis patients aged 65 and over.2023Thoracic cancerFree full text
  9. Analysis of influencing factors of postoperative myasthenic crisis in 564 patients with myasthenia gravis in a single center.2023Thoracic cancerFree full text
  10. Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort.2023Thoracic cancerFree full text
  11. Myasthenia gravis affects overall survival in patients with thymoma: an analysis of multicentre database using propensity score matching.2021Interactive cardiovascular and thoracic surgeryFree full text
All its trials on ClinicalTrials.gov, any status7
  1. An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia GravisNot yet recruitingNCT07818291Study sitePhase 1Start 2026-09
  2. A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)RecruitingNCT07249632Study sitePhase 3Start 2026-01
  3. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Study siteStart 2024-02
  4. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  5. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  6. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  7. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Study sitePhase 2Start 2020-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 4 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.1%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

8 hospitals in Beijing for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07781579

    Age not stated (registered criteria)

    Led by Beijing HospitalBeijing

  2. Recruiting
    Family-Based Moyamoya Susceptibility and Early Detection
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07517354

    Age not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStroke & bleeding outcomesRevascularisation surgeryImaging & blood flow
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

30 hospitals in Beijing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Editor's Choice - Association between Pre-operative Disease Activity and Long Term Revascularisation Outcomes in Patients with Takayasu's Arteritis: A Multicentre Retrospective Cohort Study.2025European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
Chinese-language papers (not in the count)1
  1. [Preliminary Results of Single-cell Transcriptome Sequencing in Renal Arterial Lesions of Takayasu Arteritis].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
Earlier papers (2016–2020)2
  1. Surgery and Endovascular Management in Patients With Takayasu's Arteritis: A Ten-Year Retrospective Study.2020Annals of vascular surgery
  2. Simultaneous Multi-Supra-Aortic Artery Bypass Successfully Implemented in 17 Patients with Type I Takayasu Arteritis.2018European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 8 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.8%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 2220242025: 112025

27 hospitals in Beijing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led8
  1. Co-ablation of lung malignancies with coexisting usual interstitial pneumonia: a retrospective analysis of safety and efficacy.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  2. Pirfenidone and nintedanib exert additive antifibrotic effects by the SPP1-AKT pathway in macrophages and fibroblasts.2024Biochemical and biophysical research communications
  3. Safety and efficacy of CT-guided percutaneous microwave ablation for stage I non-small cell lung cancer in patients with comorbid idiopathic pulmonary fibrosis.2024European radiology
  4. Synchronous percutaneous core-needle biopsy and microwave ablation for stage I non-small cell lung cancer in patients with Idiopathic pulmonary fibrosis: initial experience.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  5. Ginsenoside Rb1 Alleviates Bleomycin-Induced Pulmonary Inflammation and Fibrosis by Suppressing Central Nucleotide-Binding Oligomerization-, Leucine-Rich Repeat-, and Pyrin Domains-Containing Protein Three Inflammasome Activation and the NF2022Drug design, development and therapy
  6. Development and validation of the prognostic model based on autophagy-associated genes in idiopathic pulmonary fibrosis.2022Frontiers in immunology
  7. Development of a nomogram for predicting the presence of combined pulmonary fibrosis and emphysema.2021BMC pulmonary medicine
  8. Liproxstatin-1 alleviates bleomycin-induced alveolar epithelial cells injury and mice pulmonary fibrosis via attenuating inflammation, reshaping redox equilibrium, and suppressing ROS/p53/α-SMA pathway.2021Biochemical and biophysical research communications
Chinese-language papers (not in the count)1
  1. [Successful Rescue of Acute Exacerbation of Idiopathic Pulmonary Fibrosis after Surgery for Lung Cancer: Case Report].2022Zhongguo fei ai za zhi = Chinese journal of lung cancer
Earlier papers (2016–2020)2
  1. Alterations to the Lung Microbiome in Idiopathic Pulmonary Fibrosis Patients.2019Frontiers in cellular and infection microbiology
  2. Epithelium-dependent profibrotic milieu in the pathogenesis of idiopathic pulmonary fibrosis: current status and future directions.2016The clinical respiratory journal

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Beijing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Molecular genetic testing and diagnosis strategies for dystrophinopathies in the era of next generation sequencing.2019Clinica chimica acta; international journal of clinical chemistry

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

24 hospitals in Beijing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology
Papers it led2
  1. Artificial Intelligence-Driven Proteomics Identifies Plasma Protein Signatures for Diagnosis and Stratification of Behçet's Disease.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Muscle involvement in Behçet's syndrome: a case report.2025International journal of oral and maxillofacial surgery
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

32 hospitals in Beijing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led1
  1. Protective effect of modified Huangqi Chifeng decoction on immunoglobulin A nephropathy through toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-kappa B signaling pathway.2024Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
All its trials on ClinicalTrials.gov, any status2
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  2. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Beijing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Absence of tongue papillae as a sign of disease.2020Journal of the American Academy of Dermatology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京医院

Beijing Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Beijing Hospital/National Center of Gerontology; Beijing Hospital / National Center of Gerontology; Beijing Hospital/ National Center of Gerontology; Beijing Hospital for Stomatology; Beijing hospital; Beijing Hospital & National Center of Gerontology; Federal Ministry of Health Beijing Hospital

Suggest a correctionDownload the data